Skip to content
Head to head

Dianthus Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: DNTH · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

DNTH +104.5%VRTX +18.7%
It’s close.
DNTHVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price84.55515.02
Change today-0.33%-1.08%
1-year return+109.3%+22.0%
Market cap$4.76B$130.58B
52-week range35.84 – 117.88412.27 – 568.67
Valuation
P/E (TTM)-20.7233.14
P/E percentile, own 5-yr range6th99th
P/B3.846.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-4.2015.32
Net profit (TTM)$-236.51M$3.88B
Revenue (TTM)$2.72M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+205.6%+11.8%
Gross margin--85.5%
Operating margin-8683.9%33.1%
Net margin-7436.5%30.7%
Free cash flow (TTM)$-175.85M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership129.0%96.8%
Insider activity (12mo)26 buy / 24 sell28 buy / 22 sell
Short interest (% of float)16.6%1.9%
Analyst consensus100% buy (9)95% buy / 5% hold (21)
Analyst price target$135 (+59%)$624 (+21%)
StockVane view
StockVane Quant RatingD (97)C (68)
Company
Employees926,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.